Literature DB >> 29372735

Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics.

Joyce W Kamande1, Maria A M Lindell, Małgorzata A Witek, Peter M Voorhees, Steven A Soper.   

Abstract

Blood samples from patients with plasma cell disorders were analysed for the presence of circulating plasma cells (CPCs) using a microfluidic device modified with monoclonal anti-CD138 antibodies. CPCs were immuno-phenotyped using a CD38/CD56/CD45 panel and identified in 78% of patients with monoclonal gammopathy of undetermined significance (MGUS), all patients with smouldering and symptomatic multiple myeloma (MM), and none in the controls. The burden of CPCs was higher in patients with symptomatic MM compared with MGUS and smouldering MM (p < 0.05). FISH analysis revealed the presence of chromosome 13 deletions in CPCs that correlated with bone marrow results. Point mutations in KRAS were identified, including different mutations from sub-clones derived from the same patient. The microfluidic assay represents a highly sensitive method for enumerating CPCs and allows for the cytogenetic and molecular characterization of CPCs.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29372735      PMCID: PMC5877822          DOI: 10.1039/c7ib00183e

Source DB:  PubMed          Journal:  Integr Biol (Camb)        ISSN: 1757-9694            Impact factor:   2.192


  53 in total

Review 1.  Plasma cells: finding new light at the end of B cell development.

Authors:  K L Calame
Journal:  Nat Immunol       Date:  2001-12       Impact factor: 25.606

2.  Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.

Authors:  Shannon L Stott; Richard J Lee; Sunitha Nagrath; Min Yu; David T Miyamoto; Lindsey Ulkus; Elizabeth J Inserra; Matthew Ulman; Simeon Springer; Zev Nakamura; Alessandra L Moore; Dina I Tsukrov; Maria E Kempner; Douglas M Dahl; Chin-Lee Wu; A John Iafrate; Matthew R Smith; Ronald G Tompkins; Lecia V Sequist; Mehmet Toner; Daniel A Haber; Shyamala Maheswaran
Journal:  Sci Transl Med       Date:  2010-03-31       Impact factor: 17.956

3.  A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.

Authors:  Barbara Muz; Pilar de la Puente; Feda Azab; Micah John Luderer; Justin King; Ravi Vij; Abdel Kareem Azab
Journal:  Br J Haematol       Date:  2016-01-05       Impact factor: 6.998

4.  High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.

Authors:  S Bezieau; M C Devilder; H Avet-Loiseau; M P Mellerin; D Puthier; E Pennarun; M J Rapp; J L Harousseau; J P Moisan; R Bataille
Journal:  Hum Mutat       Date:  2001-09       Impact factor: 4.878

5.  Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia.

Authors:  R P Gooding; A Bybee; F Cooke; A Little; S G Marsh; E Coelho; D Gupta; D Samson; J F Apperley
Journal:  Br J Haematol       Date:  1999-09       Impact factor: 6.998

6.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

7.  Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization.

Authors:  C Pellat-Deceunynck; S Barillé; D Puthier; M J Rapp; J L Harousseau; R Bataille; M Amiot
Journal:  Cancer Res       Date:  1995-08-15       Impact factor: 12.701

8.  A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.

Authors:  Klaudia Kuranda; Céline Berthon; Caroline Dupont; Dariusz Wolowiec; Xavier Leleu; Renata Polakowska; Nathalie Jouy; Bruno Quesnel
Journal:  Exp Hematol       Date:  2009-12-03       Impact factor: 3.084

9.  Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics with an integrated conductivity sensor.

Authors:  André A Adams; Paul I Okagbare; Juan Feng; Matuesz L Hupert; Don Patterson; Jost Göttert; Robin L McCarley; Dimitris Nikitopoulos; Michael C Murphy; Steven A Soper
Journal:  J Am Chem Soc       Date:  2008-06-17       Impact factor: 15.419

10.  Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device.

Authors:  Mohammad A Qasaimeh; Yichao C Wu; Suman Bose; Anoop Menachery; Srikanth Talluri; Gabriel Gonzalez; Mariateresa Fulciniti; Jeffrey M Karp; Rao H Prabhala; Rohit Karnik
Journal:  Sci Rep       Date:  2017-04-04       Impact factor: 4.379

View more
  3 in total

Review 1.  Cell Separations and Sorting.

Authors:  Malgorzata A Witek; Ian M Freed; Steven A Soper
Journal:  Anal Chem       Date:  2019-12-20       Impact factor: 6.986

Review 2.  Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.

Authors:  Johannes M Waldschmidt; Praveen Anand; Birgit Knoechel; Jens G Lohr
Journal:  Semin Hematol       Date:  2018-03-01       Impact factor: 3.851

3.  Microfluidic Device for On-Chip Immunophenotyping and Cytogenetic Analysis of Rare Biological Cells.

Authors:  Kumuditha M Weerakoon-Ratnayake; Swarnagowri Vaidyanathan; Nicholas Larky; Kavya Dathathreya; Mengjia Hu; Jilsha Jose; Shalee Mog; Keith August; Andrew K Godwin; Mateusz L Hupert; Malgorzata A Witek; Steven A Soper
Journal:  Cells       Date:  2020-02-24       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.